+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Risk adapted chemotherapy for localised Ewing's sarcoma of bone: the French EW93 study

Risk adapted chemotherapy for localised Ewing's sarcoma of bone: the French EW93 study

European Journal of Cancer 48(9): 1376-1385

To determine whether a risk factor adapted chemotherapy would improve the outcome of non-metastatic bone Ewing's sarcoma. Standard risk tumours (SR, good histological response to chemotherapy or small unresected tumours) received the previous EW88 chemotherapy. Ifosfamide/etoposide (IE) were introduced after 3 courses of cyclophosphamide/doxorubicine when tumour regression was <50% or during consolidation therapy for the intermediate risk tumours (IR, intermediate histological response 5-30% residual cells or large unresected tumours >100ml). High risk tumours (HR, histological poor response >30% residual cells or clinical poor response <50% for unresectable tumours), received IE prior high dose busulfan/melphalan with stem cell rescue. From 1993 to 1999, 214 patients were enrolled. 5 y-EFS and OS were 60% (95% confidence interval (CI), 53-66) and 69% (95% CI, 63-75), respectively. 116 (54%), 46 (21%), 48 (22%) patients were considered as SR, IR and HR of relapse, respectively. No advantage to IE was observed in the IR group. As compared to previous study, tumour with poor histological response to induction chemotherapy seemed to benefit from the consolidation strategy including busulfan/melphalan: EFS were 45% (95% CI, 30-60) and 20% (95% CI, 7-43) for EW93 and EW88, respectively. Despite a risk-adapted strategy, histological response to chemotherapy remains the main prognostic factor in resected tumours, while initial tumour volume is the main prognostic factor for unresected tumours. These results showing a potential benefit of a consolidation strategy including busulfan/melphalan as compared to conventional chemotherapy needed confirmation by a randomised trial and were one of the bases of the ongoing EuroEwing99.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 036386941

Download citation: RISBibTeXText

PMID: 22516209

DOI: 10.1016/j.ejca.2012.03.017

Related references

Evaluation of prognostic factors in a tumor volume-adapted treatment strategy for localized Ewing sarcoma of bone: the CESS 86 experience. Cooperative Ewing Sarcoma Study. Medical and Pediatric Oncology 32(3): 186-195, 1999

Six drugs induction chemotherapy for patients with localised Ewing sarcoma (ES): A pilot study. Journal of Clinical Oncology 24(18_Suppl): 9537-9537, 2016

Is postoperative radiotherapy necessary in localised standard-risk Ewing sarcoma? : The primary tumor bulk decides upon adjuvant radiotherapy after induction chemotherapy and surgery. Strahlentherapie und Onkologie 193(1): 89-90, 2017

Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group. European Journal of Cancer 61: 128-136, 2016

Adjuvant chemotherapy in the treatment of clinically localised Ewing's sarcoma. Journal of Bone and Joint Surgery. British Volume 60-B(4): 567-574, 1978

Long-lasting multiagent chemotherapy in adult high-risk Ewing's sarcoma of bone. Medical Oncology 26(3): 276-286, 2009

Intramyofiber skeletal muscle invasion in Ewing's sarcoma of bone: clinicopathologic observations from the intergroup Ewing's sarcoma study. American Journal of Pediatric Hematology/Oncology 4(2): 231-235, 1982

Radiation therapy in the multimodality management of Ewing's Sarcoma of bone A report of the intergroup EWING'S SARCOMA study group. International Journal of Radiation Oncology*biology*physics 5(Supp-S2): 99-0, 1979

The role of radiation therapy in the management of non-metastatic Ewing's sarcoma of bone. Report of the Intergroup Ewing's Sarcoma Study. International Journal of Radiation Oncology Biology Physics 7(2): 141-149, 1981

Radiation therapy in the multimodal management of Ewing's sarcoma of bone: report of the Intergroup Ewing's Sarcoma Study. National Cancer Institute Monograph 1981(56): 263-271, 1981

Localised Ewing sarcoma/PNET of bone--prognostic factors and international data comparison. Medical and Pediatric Oncology 39(6): 586-593, 2002

Ewing's sarcoma of bone: clinicopathologic aspects of 303 cases from the Intergroup Ewing's Sarcoma Study. Human Pathology 14(9): 773-779, 1983

Ewing's sarcoma of bone tumor cells produces MCSF that stimulates monocyte proliferation in a novel mouse model of Ewing's sarcoma of bone. Bone 79: 121-130, 2015

Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. Journal of Clinical Oncology 16(11): 3628-3633, 1998

Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet. Oncology 11(6): 561-570, 2010